MerLion Pharmaceuticals Pte Ltd and Cancer Research Technology Announce Drug Discovery Collaboration
Within the collaboration MerLion will screen their natural compound collection against high throughput screens developed by scientists at CRT in order to isolate new therapeutic compounds against validated cancer targets. Targets will be selected from research carried out by Cancer Research UK and CRT's other academic partners.
Following the identification of lead compounds, it is anticipated that the expertise in medicinal chemistry both at MerLion and CRT will be utilised to perform compound optimisation. The companies will work in close partnership throughout the target selection and screening process. The results of the collaboration will be jointly owned.
This international partnership follows the Joint Statement on Science, Engineering and Technology signed by Prime Ministers Lee Hsien Loong and Tony Blair on 4th July 2005, building on the UK-Singapore Partners in Science initiative.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.